
    
      This is an open-label non-controlled, non-randomised interventional study. Study population
      consist in immunocompromised patients and older adults with or without co-morbidities.

      Included patients will receive at least one unit of convalescent plasma with NTAB titer
      â‰¥1:160 or equivalent at maximum 3-7 days after diagnosis by RT-PCR or symptom onset or if
      having mild-moderate disease (WHO scale <4).

      Patients will be followed-up up to 28 days to assess progression to WHO scale 4 disease, and
      28-days mortality and viral load kinetics.
    
  